Real-world study compares Ozempic® (semaglutide) to other standard diabetes therapies
HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. (NYSE: ANTM) and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes – one of the nation’s fastest growing chronic diseases. ... |